Combating Opioid-related Overdose
|
|
- Alisha Ross
- 5 years ago
- Views:
Transcription
1 Combating Opioid-related Overdose Kelly Dunn, Ph.D. Assistant Professor Behavioral Pharmacology Research Unit Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine
2 Presentation Outline Learn about the epidemiology of opioid overdose Understand what tools are available to help combat the opioid overdose epidemic 2
3 Treatment of Pain in the U.S. is a Billion Dollar Industry IMS Health, National Prescription Audit, Dec 2013
4 Narcotics are Among the Top 5 Prescribed Medications (2013) IMS Health, National Prescription Audit, Dec
5 Overdose is Increasing Throughout the US MMWR, Vol. 60 (43) 5
6 Overdose is Increasing Throughout the US Between , rate of drug OD increased by 137% In 2014, 47,055 people died from drug OD, 61% involved opioids Drug poisoning is the leading cause of accidental death among adults aged MMWR, Vol. 60 (43); MMWR, Vol. 64 (50),
7 Fentanyl Exposure is Also Increasing DEA-DCT-DIB DEA Intelligence Brief 7
8 Fentanyl Exposure is Also Increasing Beginning in 2013, the prevalence of fentanyl-adulterated heroin rose to unprecedented levels The rate of overdose related to fentanyl has increased 79% between 2013 and 2015 MMWR,
9 Overdose is Increasing Throughout the US Opioid OD has increased in all segments of society: Drug users Chronic pain patients Elderly Children Women Adolescents Homeless Individuals Significant risk factors for OD Detoxification Leaving jail or prison Induction onto methadone treatment When used together with alcohol or benzodiazepines Baggett et al., 2013; Bailey et al., 2009; Bohnert et al., 2011; Cobaugh et al., 2006; Coben et al., 2010; Dunn et al., 2010; Palmiere et al., 2010; Paulozzi et al., 2006; Rosca et al., 2012
10 Presentation Outline Learn about the epidemiology of opioid overdose Understand what tools are available to help combat the opioid overdose epidemic 10
11 Naloxone The majority of published opioid OD interventions focus on naloxone (Narcan) Historically available via injection
12 Naloxone Auto-injector: Evzio (Kaleo Inc.) Approved by FDA on 4/3/2014
13 Approved by FDA on 11/18/2015 Narcan
14 IN vs. IV naloxone Time to Spontaneous Respiration (min) Time to Glascow Coma Score Kelly et al., 2005; Medical Journal of Australia
15 TM Exonal
16 Dunn et al., unpublished Naloxone Formulations
17 Dunn et al., unpublished Naloxone Formulations
18 Wheeler et al., 2015, MMWR Bystander Interventions
19 Efforts to Develop a Brief Screen The majority of opioid OD interventions focus on naloxone (Narcan) Non-naloxone approaches important because: Naloxone is not available everywhere Naloxone requires training to administer Price of naloxone has increased substantially Naloxone has many legal barriers Naloxone reverses OD but is not necessarily preventative Naloxone may not reverse OD that occurs with concurrent alcohol/benzodiazepine use
20 Brief Opioid Overdose Knowledge (BOOK) Questionnaire Identified 59 OD risk behaviors from literature, developed self-report measure Data collected in 3 phases Phase 1: Opioid users (N=147) recruited from detoxification settings Phase 2: Opioid users (N=199) recruited from MAT, detoxification, & needle exchange in VT and MD Phase 3: Patients currently prescribed opioids for the treatment of chronic pain (N=502), recruited via Amazon Mechanical Turk crowdsourcing Dunn et al., 2016, Journal of Addiction Medicine
21 Brief Opioid Overdose Knowledge (BOOK) Questionnaire Illicit Users Illicit Users Chronic Pain (Sample 1) (Sample 2) (Sample 3) (N=147) (N=199) (N=502) p-value a Aged over 30 (%) Male (%) <.001 Caucasian (%) <.001 Never Married (%) <.001 Employed (%) <.001 Overdosed on opioids (%) <.001 Witnessed an overdose (%) <.001 Trained to administer naloxone (%) <.001 a Values based on chi-square comparisons Symbols designate significant between-group differences. Shared symbols represent no siginificant difference between groups at p<.05 Dunn et al., 2016, Journal of Addiction Medicine 21
22 Brief Opioid Overdose Knowledge (BOOK) Questionnaire 12 True/False/I don t know items General knowledge (4 items) e.g. long vs short acting drugs, withdrawal signs Overdose risk knowledge (4 items) e.g. OD signs and symptoms; drug combos Overdose response knowledge (4 items) E.g. rescue breathing; Narcan Dunn et al., 2016, Journal of Addiction Medicine 22
23 Brief Opioid Overdose Knowledge (BOOK) Mean Correct Responses (range 0-4) Performance on BOOK Subscales p<.001 Dunn et al., 2016, Journal of Addiction Medicine Questionnaire Illicit Users (Samples 1 & 2) Chronic Pain Patients (Sample 3) ns General Opioid Opioid OD Risk Knowledge Subscale p<.001 Opioid OD Response
24 OD in Chronic Pain Patients Surveyed 501 individuals who reported pain in past 3 months and treatment with opioid OD Experience 19.3% had experienced an OD 37.8% had witnessed an OD Only 3% had been trained to administer naloxone Past 30 day behaviors: 53.8% had used opioids alone 37.5% had combined opioids with alcohol Predominate RXOP users Dunn et al., 2016, Pain Medicine 24
25 OD in Chronic Pain Patients Evaluated numerous predictors of OD. Only 2 items emerged: SOAPP-R, DSM Checklist ROC analyses revealed that established cutoffs on two measures predicted history of OD: Screener and Opioid Assessment for Patients with Pain (SOAPP-R) >7 Mild Opioid Use Disorder (>2 items) Dunn et al., 2016, Pain Medicine
26 OD in Rural vs. Urban Settings Surveyed 345 individuals with opioid use disorder in rural (n=98) and urban (n=247) settings OD Experience 35.6% had experienced an OD 67.5% had witnessed an OD Only 16.9% had been trained to administer naloxone Past 30 day behaviors: 55.1% had used opioids alone 45.6% had combined opioids with alcohol Predominate heroin users 26 Dunn et al., in press, Pain Medicine
27 OD in Rural vs. Urban Settings Table 2. Overdose History and Risk Factors Entire Sample Participants with History of Overdose Total Rural Urban p-value Total OD Rural OD Urban OD p-value (N=345) (N=98) (N=247) (N=123) (N=45) (N=78) Overdose (OD) History Lifetime Overdose (%) < N/A Number ODs (mean times, SD) a 1.3 (2.2) 1.5 (2.5) 1.0 (2.0) (2.6) 3.3 (2.8) 3.1 (2.4) 0.66 OD past 30 days (%) OD past year (%) Gone to Emergency Department for OD (%) Witnessed OD (%) Naloxone History Received naloxone prescription (%) < <.001 Trained to administer naloxone (%) < <.001 Trained to administer CPR (%) <.01 Past 30 Day Risk Behaviors (%) Used opioids by themselves <.001 Number days past 30 (mean days, SD) a 2.0 (2.3) 1.2 (1.9) 2.7 (2.6) < (2.0) 1.0 (1.6) 3.2 (2.5) <.001 Combining opioids with alcohol < <.001 Number days past 30 (mean days, SD) a 1.5 (2.0) 0.7 (1.5) 2.2 (2.6) < (1.9) 0.5 (1.2) 2.5 (2.5) <.001 Using methadone < <.01 Number days past 30 (mean days, SD) a 0.3 (.93) 0.1 (.53) 0.5 (1.4) < (.85) 0.1 (.47) 0.5 (1.2) 0.06 Undergoing detoxification from opioids < <.001 Number days past 30 (mean days, SD) a 0.5 (.99) 0.2 (.71) 0.9 (1.27) < (.76) 0.1 (.25) 0.9 (1.3) <.001 Been in jail or prison Number days past 30 (mean days, SD) a 0.2 (.07) 0.1 (.45) 0.2 (.91) (.39) 0.2 (.56) 0.1 (.22) 0.15 P-values based on Chi-squares for dichotomous variables and independent groups t-tests for continuous variables. OD=overdose; SD=standard deviation a Represents mean reported by participants who endorsed the event b Defined as stimulants and/or benzodiazepines Dunn et al., 2016, 27 JSAT
28 OD in Rural vs. Urban 1 Settings Mean (SEM) C Only predictor of OD was performance on the BOOK Opioid and Knowledge Domain Opioid OD Knowledge subscales 0 General Opioid Opioid OD Risk Opioid OD Response Mean (SEM) Correct Responses All 2D Participants Graph 2 4 Rural (N=98) Urban (N=247) Mean (SEM) Correct Responses D Graph 2 Participants with a History of OD * * Rural (N=45) Urban (N=78) * 0 General Opioid Opioid OD Risk Opioid OD Response Knowledge Domain 0 General Opioid Opioid OD Risk Opioid OD Response Knowledge Domain 2D Graph 2 Dunn et al., 2016, 28 JSAT
29 Opioid OD Knowledge Intervention Educational interventions Strengths: Show immediate and sustained gains in knowledge Limitations: Not yet evaluated in RCT Generally targeted towards drug users Often administered by trained professional in individualized or group settings Majority of published interventions focus primarily on naloxone administration Green et al., 2008; Piper et al., 2007; Strang et al., 2008; Tobin et al., 2009; Wagner et al., 2010
30 Opioid OD Knowledge Intervention RCT of an educational intervention Randomized to 1 of 3 groups: Pamphlets Computer intervention Computer intervention with questions Complete pre and post knowledge test; Single administration of intervention Complete 1 and 3 month follow-ups to assess extended knowledge
31 Opioid OD Knowledge Intervention
32 Opioid OD Knowledge Intervention
33 Opioid OD Knowledge Intervention
34 Opioid OD Knowledge Intervention Opioid users (N=76) recruited from 3-5 day outpatient buprenorphine detoxification program OD Experience 36.0% had experienced an OD 53.6% had witnessed an OD Only 10.6% had been trained to administer naloxone Past 30 day behaviors: 56.0% had used opioids alone 91.2% had combined opioids with alcohol Predominate heroin users 34 Dunn et al., under review
35 Opioid OD Knowledge Intervention 100 Opioid Knowledge Opioid OD Knowledge Opioid OD Response Knowledge 80 Mean Percent Pre Pamphlet Computer Computer + Mastery Timepoint Post Pre Timepoint Post Pre Timepoint Post Dunn et al., under review
36 Opioid OD Knowledge Intervention The majority (87%) of participants had relapsed to opioids 9.4% had witnessed an OD by the 30-day follow-up Significant reductions in number of days used opioids alone in past 30, and combining opioids and alcohol 36 Dunn et al., under review
37 Opioid OD Knowledge Intervention 100 Opioid Knowledge Opioid OD Knowledge Opioid OD Response Knowledge Mean Percent Correct Pamphlet Computer Computer + Mastery Pre. Post 1 m 3 m Timepoint Pre. Post 1 m 3 m Timepoint Pre. Post 1 m 3 m Timepoint Dunn et al., under review
38 Opioid OD Knowledge Intervention The Educational Intervention: a Pamphlet Computer Computer + Mastery (N=25) (N=24) (N=27) Was helpful 1.6 (0.9) 1.4 (0.9) 1.6 (0.9) 0.73 Taught me information I did not know before 1.6 (0.7) 1.5 (0.9) 1.5 (0.9) 0.21 Was easy to understand 1.9 (0.9) 1.3 (0.5) 1.5 (0.5) 0.03 Was fun 2.6 (1.2) 2.3 (0.9) 2.2 (1.1) 0.42 Took too long 2.7 (1.3) 3.3 (1.0) 3.2 (1.4) 0.14 Was Interesting 2.2 (1.2) 1.8 (1.0) 1.7 (0.7) 0.33 I would recommend this educational intervention to someone else a 2.2 (1.1) 1.5 (1.0) 1.7 (0.9) 0.20 I believe that more people should receive this educational intervention a 1.8 (1.2) 1.4 (1.0) 1.6 (1.0) 0.43 I DO NOT think that the educational intervention was useful a 4.0 (1.3) 4.2 (1.0) 4.3 (0.9) 0.47 The educational intervention was confusing a 3.7 (1.3) 4.2 (1.0) 3.9 (1.1) 0.05 How important is it to learn to prevent, recognize, and respond to an overdose b 2.0 (0) 2.0 (0) 2.0 (0.2) 0.39 This intervention will help me from overdosing in the future (%) Feel this intervention will change the way you help people who are overdosing (%) Would recommend this intervention to a family member or friend (%) a Rated on 5-point Likert Scale: 1=Strongly Agree, 2=Agree, 3=Neither Agree not Disagree, 4=Disagree, 5=Strongly Disagree b Rated on 3-point Likert Scale: 0=Not at all Important, 1=Somewhat Important, 2=Very Important p-value Dunn et al., under review
39 Conclusions Opioid OD is a serious public health problem Brief Opioid Overdose Knowledge (BOOK) may have value as an outcome measure and clinically to inform conversations with patients Risk behaviors and low knowledge are prevalent across multiple different populations Computer-based intervention produces sustained gains in knowledge
40 Acknowledgements Many thanks to the Johns Hopkins Chemical Dependency Unit, Kathy Petrush, Suzan Berman, Anne Kelly, Carl Broker, and Eric Cunningham NIDA: R21 DA035327; R01DA Thank you! Contact me at: Kelly Dunn, Ph.D. P:
41 Dunn et al., under review 41
Understanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationReducing opioid overdose mortality: role of communityadministered
Reducing opioid overdose mortality: role of communityadministered naloxone Vennus Ballen, MD, MPH; Lara Maldjian, MPH New York City Department of Health and Mental Hygiene Clinical Director s Network (CDN)
More informationAnyone Can Become Addicted. Anyone.
Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.
More informationCampus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING
Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING Opioid Epidemic Prescription Opiods Can be prescribed by doctors to treat moderate to severe pain, but can also have serious risks and side
More informationTake Home Naloxone: Law Update and Considerations for Pharmacy Professionals
Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Clint Ross, PharmD, BCPP Clinical Pharmacy Specialist Psychiatry Residency Program Director Psychiatric Pharmacy Medical University
More informationThe Role of Urgent Care in responding to the opioid Crisis
The Role of Urgent Care in responding to the opioid Crisis Robert S Crausman MD MMS Partner, Ocean State Urgent Care and Primary Care Centers Clinical Professor of Medicine, Brown Rob@OSUC.net Opioid Crisis
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationNARCAN: THE HISTORY, APPLICATIONS AND FUTURE
NARCAN: THE HISTORY, APPLICATIONS AND FUTURE TABLE OF CONTENTS 3 Intro 4 What is Naloxone? 8 How Naloxone is Administered 12 Where to Find Narcan in California The United States accounts for about five
More informationNARCAN? YOU CAN!: A LEGISLATIVE & CLINICAL UPDATE ON NALOXONE
NARCAN? YOU CAN!: A LEGISLATIVE & CLINICAL UPDATE ON NALOXONE Stephanie Nichols, PharmD, BCPS, BCPP Associate Professor, Husson University Nicholss@husson.edu Why did you become a pharmacy professional?
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationNaloxone (Narcan) Initiatives and the Court System
Naloxone (Narcan) Initiatives and the Court System Jolene Defiore-Hyrmer, Section Chief Violence and Injury Prevention Section 2018 Specialized Docket Conference October 12, 2018 2:45-4:00 Learning Objectives
More informationOpportunities for Opioid Safety and Community-Based Overdose Management
Opportunities for Opioid Safety and Community-Based Overdose Management DANTE COLLINS ERICA C. ERNST MAYA DOE-SIMKINS SEPTEMBER 13, 2013 Overview Prevalence & data Overdose prevention Making an overdose
More informationNaloxone: Preventing Opioid Overdose in the Community. Sharon Stancliff, MD Medical Director Harm Reduction Coalition
Naloxone: Preventing Opioid Overdose in the Community Sharon Stancliff, MD Medical Director Harm Reduction Coalition DISCLOSURES Sharon Stancliff MD has nothing to disclose LEARNING OBJECTIVES 1. Discuss
More informationDrug Class Review: Opioid Reversal Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationResearch on opioid overdose and naloxone distribution in San Francisco: from epidemiology to intervention development to implementation.
Research on opioid overdose and naloxone distribution in San Francisco: from epidemiology to intervention development to implementation. Alex H. Kral, PhD Director Behavioral and Urban Health Program RTI
More informationTake Home Naloxone: What Pharmacists Need to Know
Take Home Naloxone: What Pharmacists Need to Know Sheri L. Fandrey, BSP, PhD Knowledge Exchange Lead Manitoba Addictions Knowledge Exchange Conflict of Interest/Disclosure Dr. Sheri Fandrey Has no conflicts
More informationPrescription for Progress Study conducted by the Siena College Research Institute April 10 - May 4, Stakeholders - MOE +/- 4.
How serious a public health problem in the State of New York is each of the following: [Q1A-Q1I ROTATED] Q1A. Alcohol abuse Very serious 61% 63% 53% 63% 36% 71% 52% Somewhat serious 35% 35% 38% 33% 52%
More informationMEDICATION ASSISTED TREATMENT
MEDICATION ASSISTED TREATMENT MODULE 14 ALLIED TRADES ASSISTANCE PROGRAM PREVENTATIVE EDUCATION: SUBSTANCE USE DISORDER Medication Assisted Treatment Types of Medication Assisted Treatment: Methadone Naltrexone
More informationOpioids and Overdose 2017
Opioids and Overdose 2017 This presentation is an introduction to: 1. Opioids, overdose and naloxone 2. How you can help A partnership of: Opioids A class of drugs taken for pain relief or euphoria. Prescribed
More informationOpioid education programs and nasal naloxone rescue kits
Opioid education programs and nasal naloxone rescue kits Arne Skulberg PhD student NTNU Consultant Anaesthetist, Oslo Epidemiology Europe 2 Epidemiology US 200 % increase in opioid overdoses since 2000.
More informationPrescription Opioids
What are prescription opioids? Prescription Opioids Opioids are a class of drugs naturally found in the opium poppy plant. Some prescription opioids are made from the plant directly, and others are made
More informationNaloxone for Opioid Safety
Naloxone for Opioid Safety Phillip O. Coffin, MD MIA San Francisco Department of Public Health University of California San Francisco Disclosure Information Gilead, Donated ledipasvir-sofosbuvir, Study,
More informationNALOXONE LEARNING ABOUT NALOXONE COULD SAVE A LIFE
NALOXONE LEARNING ABOUT NALOXONE COULD SAVE A LIFE WHAT IT IS WHAT IT IS NARCAN (naloxone HCl) Nasal Spray is the first and only FDA-approved nasal form of naloxone for the emergency treatment of a known
More informationWho is Behind the Opioid Epidemic?
Safe and Effective Management of Pain and Addiction CARL CHRISTENSEN, MD PHD MEDICAL DIRECTOR, DAWN FARM CLINICAL ASSOCIATE PROFESSOR, WSU SCHOOL OF MEDICINE WWW.CHRISTENSENRECOVERY.COM Tonight s Talk:
More informationOpioid Overdose: Risks, Clinical Features, Treatment, and Reduction of Negative Consequences
Opioid Overdose: Risks, Clinical Features, Treatment, and Reduction of Negative Consequences Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry
More informationNaloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no
THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any
More informationPrescribing Naloxone to Patients for Overdose Reversal
Prescribing Naloxone to Patients for Overdose Reversal Module Author: Julie Kmiec, DO Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine Addiction Psychiatry - Western Psychiatric
More informationTake Home Naloxone Report on supply and use to reverse an overdose
Take Home Naloxone Report on supply and use to reverse an overdose 2012-2016 1 Contents 1. Introduction 2. How the Take Home Naloxone Programme works 3. How information is collected 4. Patients supplied
More informationMedication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford
Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand
More informationTake Home Naloxone elearning Module Script
elearning Module Script Slide 1-3 Review the outline and the plan for the presentation. Slide 4 We do accept the cynicism of this poster. Slide 5 Read from the slide the definition of Harm Reduction Slide
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationWelcome to the Opioid Overdose Prevention Project
Welcome to the Opioid Overdose Prevention Project Narcan Training TODAY S OBJECTIVES Define drug addiction Identify symptoms of addiction Treatment options including support for family members How to recognize
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationProviding Medication Assisted Treatment for Opioid Use Disorder in Family Medicine Clinics in Vermont
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Providing Medication Assisted Treatment for Opioid Use Disorder in Family Medicine Clinics
More informationOpioid Harm Reduction
Opioid Harm Reduction Lucas G. Hill, PharmD Clinical Assistant Professor, The University of Texas at Austin College of Pharmacy Clinical Pharmacist, CommUnityCare FQHCs Director, Operation Naloxone Mark
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationNaloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties
Naloxone Statewide Standing Order Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties Objectives Review the US & NC trends on opioid overdose Understand key
More informationAdvancing Addiction Science to Address the Opioid Crisis
Advancing Addiction Science to Address the Opioid Crisis National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director National Institute
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationFigure 1. National Drug Overdose Deaths Number Among All Ages, by Gender,
Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender, -217 1, Total Overdose Deaths Male Female 8, 7,237 6, 4, 16,849 2 21 22 23 24 36,1 25 26 27 28 29 21 211 212 213 214 215 216 217-217
More information8/12/2013. Drug overdose death rates in the US have more than tripled since 1990 (CDC 2011).
Age Adjusted Death Rate/100,000 p-y 8/12/2013 Jane A. Kennedy, D.O. Lisa Raville, B.A. Executive Director, Harm Reduction Action Center Slide presentation about opioids, overdose, and Naloxone Many thanks
More informationHARM REDUCTION & TREATMENT. Devin Reaves MSW
HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that
More informationNIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse
NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse Virtually All of the U.S. Have Increased Drug Overdoses:
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationTELEPHONE SCREENING DEMOGRAPHIC INFO
TELEPHONE SCREENING Provider Name: Provider Signature: Date: How did you hear about the hotline? DEMOGRAPHIC INFO 1 = Spouse 2 = Friend 3 = Medical Provider 4 = Flyer 5 = Parent 6 = State Hotline 7 = Physician
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationPediatric Toxicology Update
Pediatric Toxicology Update Suzan S Mazor MD Associate Professor Pediatric Emergency Medicine Medical Toxicology Seattle Children s Hospital University of Washington School of Medicine Washington Poison
More informationMobilizing a Response to the Opioid Epidemic: County Snapshots. Kelly Pfeifer, MD May 10, 2018
Mobilizing a Response to the Opioid Epidemic: County Snapshots Kelly Pfeifer, MD kpfeifer@chcf.org May 10, 2018 Housekeeping All lines are muted This session will be recorded To ask a question: Questions
More informationVermont Hub and Spoke Model Treatment Need Questionnaire
Vermont Hub and Spoke Model Treatment Need Questionnaire Friday, June 30, 2017 John Brooklyn, MD Assistant Professor of Family Medicine and Psychiatry University of Vermont Burlington, Vermont Webinar
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationNaloxone Administration Training
Naloxone Administration Training Welcome! Welcome to the online training for naloxone administration The Presenter Dr. Joe Parks, Medical Director, Distinguished Professor, Missouri Institute for Mental
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationAetna s Initiative on the Opioid Epidemic
Aetna s Initiative on the Opioid Epidemic Christopher James D.O., M.P.H. Medical Director, BH- Mid-Atlantic Territory (JamesC1@aetna.com) July 23, 2017 HHS Data on Epidemic Every Day in the U.S. More than
More informationHow does polydrug use contribute to heroin overdose deaths? Risk to heroin users of concurrent use of pregabalin and gabapentin
How does polydrug use contribute to heroin overdose deaths? Risk to heroin users of concurrent use of pregabalin and gabapentin Graeme Henderson Suzanne Audrey Matt Hickman Abi Lyndon Rob Hill Claudia
More informationPatient and Family Agreement on Opioids
Patient and Family Agreement on Opioids We care about our patients and are committed to their recovery and wellness. We offer our patients medications and options for various services to keep them from
More informationWhat is the strategy?
What is the strategy? Multi-pronged approaches to reducing the health consequences of opioid use, New York City Northeast Epidemiology Conference Public health approach Track drug use and associated health
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D.. Executive Director, Physicians for Responsible Opioid Prescribing Senior Scientist, Heller School
More informationOHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS
OHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements found in the opium poppy plant. These drugs are
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationJournal Club: Naloxone Programs in the Community and Their Success to Decrease Overdoses from Opioids
Journal Club: Naloxone Programs in the Community and Their Success to Decrease Overdoses from Opioids Emily Junck, MD Hayes Wong, MD Paul Freeman, MD Special Guest: Caleb Banta-Green, PhD, MPH, MSW Special
More informationUsing Naloxone to Reduce the Number of Opioid Overdose Deaths Among Clackamas County Inmates Post-Release
Using Naloxone to Reduce the Number of Opioid Overdose Deaths Among Clackamas County Inmates Post-Release Apryl L. Herron, MPH Clackamas County Public Health Division Kristen Watson, CADC II, QMHA Clackamas
More informationNALOXONE: HEALTHCARE PROFESSIONALS TRAINING GUIDE FOR ADMINISTRATION AND DISPENSING
NALOXONE: HEALTHCARE PROFESSIONALS TRAINING GUIDE FOR ADMINISTRATION AND DISPENSING Kaitlyn Bernard, PharmD PGY-1 Pharmacy Practice Resident November 18, 2017 Objectives Explain the impact of the opioid
More informationAdvancing Addiction Science to Address the Opioid Crisis
Advancing Addiction Science to Address the Opioid Crisis National Institute on Drug Abuse Bringing the full power of science to bear on drug abuse and addiction Nora D. Volkow, M.D. Director National Institute
More informationSUBSTANCE ABUSE IN THE ELDERLY. The Invisible Epidemic
SUBSTANCE ABUSE IN THE ELDERLY The Invisible Epidemic IS IT POSSIBLE TO TEACH AN OLD DOG NEW TRICKS? GUIDELINES All forms of addiction know no age limit. Don t blame all problems on aging. Few realize
More informationNaloxone for Emergency Administration: A 2017 Update On FDA Guidance
Naloxone for Emergency Administration: A 2017 Update On FDA Guidance Nathan A. Painter, PharmD, CDE Associate Clinical Professor University of California San Diego Skaggs School of Pharmacy and Pharmaceutical
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationThe Prescription Opioid and Heroin Crisis
The Prescription Opioid and Heroin Crisis Dr. Rachel L. Levine Acting Secretary of Health and Physician General Professor of Pediatrics and Psychiatry Penn State College of Medicine Overdose deaths from
More informationPREVENTING OPIATE OVERDOSES IN SCHOOLS. Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region
PREVENTING OPIATE OVERDOSES IN SCHOOLS Head 2 Toe 2017 April 20, 2017 Winona Stoltzfus BSN, MD, School Health Officer and Acting RHO SE Region WHY IS THIS EVEN A QUESTION FOR SCHOOLS? In 2014, 467,000
More informationResponding to the Opioid Epidemic
Responding to the Opioid Epidemic Jessica Gray, MD Addiction Medicine Fellow Boston Medical Center ROME New England August 17, 2017 Disclosures for Jessica Gray, MD No conflicts Learning Objectives Describe
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationStrategies to Manage The Opioid Crisis
Strategies to Manage The Opioid Crisis Matt Feehery, LCDC Senior Vice President & CEO PaRC (Prevention & Recovery Center) Behavioral Health Services February 1, 2018 A Pill for Your Pain But my doctor
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationMedical vs. Use of Drugs. Warning Signs of Chemical Dependence. Intent Effect. Legality Pattern 5/5/2010. Daily use above ceiling doses
Identifying and Preventing Drug Abuse By: Lon R. Hays, M.D., M.B.A. Professor and Chairman Department of Psychiatry University of Kentucky Healthcare Medical vs. Non-Medical Use of Drugs Intent Effect
More informationOverdose Prevention: Empowering School Personnel & Families
Overdose Prevention: Empowering School Personnel & Families Christopher Welsh M.D. University of Maryland School of Medicine NCADD-Maryland Scientific Advisory Committee INITIATION OF DRUG USE >12 Y.O.(2013;
More informationPregnancy, MAT and Addiction
Pregnancy, MAT and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine William Morrone, DO, MPH, DABAM Covenant Hospital
More informationOpioid Overdose Education and Naloxone Distribution
Opioid Overdose Education and Naloxone Distribution Emily Stoukides, PharmD PGY-2 Ambulatory Care Pharmacy Resident Nicole Brunet, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health Disclosures Emily
More informationEarl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction
Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Thank you, Chairman Rogers, for holding this important Summit and helping to bring attention
More informationNaloxone and Combating the Opioid Epidemic
Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to
More informationOur Opioid Epidemic. The Opioid Mortality Crisis Continues 3/2/2017 STEPHEN R. BELL, DO
Our Opioid Epidemic STEPHEN R. BELL, DO GOVERNOR S TASK FORCE ON PRESCRIPTION DRUG AND OPIOID ABUSE MICHIGAN STATE COMMISSION ON OPIOID AND PRESCRIPTION DRUG ABUSE CHAIR, MOA PRESIDENTIAL TASK FORCE ON
More informationAcademic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationMEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER
MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER JOHN E LOPES Jr., DHSC, PA-C Associate Professor, Physician Assistant Program Central Michigan University and Project Director Medication-assisted
More informationSteve Alsum. The Grand Rapids Red Project. (616)
Steve Alsum The Grand Rapids Red Project steve@redproject.org (616) 456-9063 Red Project Basics Overdose Epidemiology Naloxone Distribution Overview Locally And In Michigan Innovative National Models A
More informationChanging Course: statewide efforts to combat the opioid epidemic in California
Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries
More informationOVERDOSE PREVENTION AND EDUCATION OVERDOSE MANAGEMENT
OVERDOSE PREVENTION AND EDUCATION OVERDOSE MANAGEMENT 1 OBJECTIVES Discuss basics of opioid overdose epidemiology and physiology To share accurate information about overdose prevention and education including
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationNew Guidelines for Prescribing Opioids for Chronic Pain
New Guidelines for Prescribing Opioids for Chronic Pain Andrew Lowe, Pharm.D. CAPA Meeting October 6, 2016 THE EPIDEMIC Chronic Pain and Prescription Opioids 11% of Americans experience daily (chronic)
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Institute for Behavioral Health Schneider Institutes
More informationOPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)
OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) Case 105- Prep Materials University of Massachusetts Medical School Opioid Conscious Curriculum Learner Prep Objectives The purpose of this prep material
More informationHARM REDUCTION & THE OPIOID EPIDEMIC. CHELSEA RAINWATER Co-Founder & Executive Director No Overdose Baton Rouge
HARM REDUCTION & THE OPIOID EPIDEMIC CHELSEA RAINWATER Co-Founder & Executive Director No Overdose Baton Rouge NO OVERDOSE BATON ROUGE Formed in late 2013 Community education Naloxone distribution Syringe
More informationHarm Reduction 10/17/2018. Topics for Today. Working Definition of Harm Reduction
Harm Reduction Dennis Radloff Human Services Program Coordinator Substance Abuse Services Topics for Today Overview of harm reduction Sterile syringe access programs Preventing fatal opioid overdoses Working
More informationOpioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative
Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D.. Executive Director, Physicians for Responsible Opioid Prescribing Senior Scientist, Heller School
More information